Incannex Regains Nasdaq Footing, Sharpening Focus on High-Value Drug Pipeline

MELBOURNE, Australia and NEW YORK – March 17, 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL) has successfully navigated a critical market challenge, announcing today that it has regained full compliance with Nasdaq's minimum bid price requirement. The development removes a significant cloud of uncertainty that has hovered over the clinical-stage biopharmaceutical company, allowing management to pivot its full attention and substantial resources toward its ambitious pipeline of novel combination therapies.

In a written confirmation, The Nasdaq Stock Market LLC verified that Incannex had satisfied the listing requirements after its common stock closed at or above $1.00 per share for eleven consecutive business days, from February 27 through March 13, 2026. This milestone officially closes the compliance matter that began in September 2023, when the company was first notified of the deficiency.

Overcoming the Technical Overhang

For many development-stage biopharmaceutical companies, maintaining Nasdaq listing status is more than a formality; it is a vital sign of market viability. A failure to meet the minimum bid price rule can trigger a delisting process, which often spooks investors, hampers capital-raising efforts, and can become a major distraction for leadership.

Joel Latham, President and Chief Executive Officer of Incannex, addressed this directly in a statement. “We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement, which reinforces our continued listing on the Nasdaq Capital Market and removes a technical overhang that has weighed on the Company,” he said.

This 'technical overhang' is a common challenge in the volatile biotech sector, where stock prices can be swayed by clinical trial timelines, regulatory news, and broader market sentiment, often disconnecting from a company's fundamental progress. By resolving the issue, Incannex has stabilized its position in the public market, providing a more secure platform for existing and potential investors.

A Strong Financial Position in a Capital-Intensive Race

Beyond the Nasdaq compliance, what sets Incannex apart in the current economic climate is its robust financial health. The company reports a formidable balance sheet with approximately $75 million in cash and, notably, no debt. This financial war chest is a critical asset in the world of drug development, a notoriously long and expensive endeavor.

The 'cash runway'—the length of time a company can fund its operations before needing additional financing—is a key metric for investors. With a substantial cash reserve, Incannex is well-positioned to fund its planned clinical programs without the immediate pressure of seeking capital in potentially unfavorable market conditions. This allows the company to pursue its development strategy from a position of strength, focusing on achieving clinical milestones rather than short-term financial survival.

“With approximately $75 million in cash, no debt, and a disciplined development strategy, we believe Incannex is exceptionally well positioned to advance our pipeline of differentiated clinical programs,” Latham added, underscoring the strategic advantage this financial stability provides.

A Pipeline Targeting Major Unmet Needs

With the listing issue resolved and its finances secure, the spotlight returns to Incannex’s core mission: developing innovative treatments for conditions with limited or inadequate options. The company’s strategy hinges on creating proprietary combination therapies, which pair existing drug compounds to create a synergistic effect that is more powerful than either agent alone. This approach can potentially offer a more efficient and de-risked path to regulatory approval.

Two programs in particular stand at the forefront of its efforts:

• IHL-42X for Obstructive Sleep Apnea (OSA): This is Incannex’s lead candidate, an oral fixed-dose combination of dronabinol and acetazolamide. OSA is a widespread and serious condition that affects millions globally, characterized by repeated breathing interruptions during sleep. The current standard of care is the Continuous Positive Airway Pressure (CPAP) machine, which many patients find cumbersome and difficult to tolerate. A safe and effective oral pharmaceutical would represent a paradigm shift in treatment. Incannex has already reported statistically significant results from its Phase 2 study, a major validation of the drug’s potential.

• PSX-001 for Generalized Anxiety Disorder (GAD): This program involves an oral synthetic psilocybin treatment aimed at GAD, a chronic and pervasive mental health condition. While existing treatments like SSRIs are available, they are not effective for all patients and can come with undesirable side effects. The therapeutic potential of psychedelics, administered in a controlled clinical setting, is one of the most exciting frontiers in modern psychiatry. Incannex has noted positive clinical outcomes for PSX-001, positioning it in a rapidly emerging and high-interest therapeutic area.

Incannex is also advancing IHL-675A, a combination of cannabidiol and hydroxychloroquine, for inflammatory conditions like rheumatoid arthritis. Across its portfolio, the company is targeting multi-billion dollar markets where a significant portion of patients are underserved by current therapies.

As the company moves forward, its primary objective is to continue advancing these programs through the rigorous clinical trial process. “As we progress these programs through upcoming milestones, our focus remains on executing our clinical strategy, further de-risking our assets, and unlocking the long-term value of our pipeline for patients and shareholders,” concluded Latham. With its market standing secured and its finances in order, Incannex is now free to concentrate on the scientific and clinical execution that will ultimately define its success.